The Food and Drug Administration has released the proposed rule that would end a decades-old arrangement allowing companies to introduce food ingredients into the American supply without ever telling the federal government.
The proposal, announced by the Department of Health and Human Services on Monday and published in the Federal Register the following day, would convert a voluntary notification program into a mandatory one. Under the current system, a company can convene its own panel of experts, conclude that an ingredient is Generally Recognized as Safe, and market it without filing anything with the FDA.
For shoppers, the immediate practical effect is negligible. Nothing is being pulled from shelves, no ingredient has been declared unsafe, and the earliest date any company would have to comply is at least two years away. What the proposal changes is the information the government and the public would eventually have.
The Self-Affirmation Pathway, Explained
The Federal Food, Drug, and Cosmetic Act requires premarket review of substances added to food unless those substances are generally recognized as safe by qualified experts. Congress established that exemption in 1958, and it was written for long-familiar ingredients rather than novel compounds.
Over time, it grew into something broader. FDA regulations permit a company to reach its own GRAS conclusion and act on it. Filing a notice with the agency has been optional, and there is no complete public registry of ingredients that entered the food supply this way. That means neither regulators nor consumers can produce a full list of what has been added under the pathway.
MedicalDaily reported earlier this month on how the self-affirmation gap works and the state bills targeting it. What has changed since then is that the rule text now exists.
A Notification Requirement, Not a Safety Verdict
The distinction matters and is easy to lose. The proposed rule would require the submission of GRAS notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use. It covers ingredients added directly to food and substances that migrate indirectly, such as from packaging.
It would not create a premarket approval process. The agency would gain visibility, not a veto.
The Department of Health and Human Services said the change would modernize the framework by making notifications mandatory and expanding the public-facing inventory of submitted notices. For substances already on the market based on a company's GRAS conclusion, the proposal would establish a time-limited, streamlined submission pathway rather than requiring every existing determination to undergo full notification.
The proposal would also let the FDA revisit earlier GRAS conclusions, ask follow-up questions about previously submitted notices, and update or rescind prior letters in which it raised no objection. Acting FDA Commissioner Kyle Diamantas said the requirement would close critical information gaps and give the agency greater visibility into substances entering the food supply.
Timelines Stretch Years Beyond the Announcement
Nothing takes effect on the announcement. The FDA is accepting public comments for 120 days following publication in the Federal Register, with comments due by December 9, under docket number FDA-2025-N-3262. Comments may be filed by anyone through Regulations.gov.
If the rule is finalized as proposed, it would take effect 60 days after the final version is published, with compliance required 18 months after that, according to an analysis by the law firm Keller and Heckman.
That sequence means a realistic compliance date well into the latter half of the decade, assuming the rule is finalized without significant delay.
Legal Challenges Are Already Anticipated
There is a live question about whether the FDA can require this under existing law. Attorneys reviewing the proposal have flagged the agency's legal authority to compel notification as an open issue, and courts no longer defer automatically to agency interpretations of ambiguous statutes.
HHS Secretary Robert F. Kennedy Jr. said during the announcement that Congress may need to provide the FDA with additional tools and authorities, a statement that acknowledges the constraint rather than resolving it.
Separately, several states have moved on their own. Legislation in New York, Pennsylvania, California, and New Jersey would require ingredient reporting at the state level, with several of those bills reaching substances already on the market. New York's version passed both legislative chambers this spring and awaits action by the governor. Because no federal proposal preempts state law, a patchwork of state disclosure rules remains a plausible outcome regardless of what happens at the federal level.
The proposal also reaches food packaging. Substances that migrate into food from containers and processing equipment would fall under the notification requirement, and the agency has proposed expanding an existing threshold-of-regulation process for those materials. That is a category most shoppers never think about, and it accounts for a meaningful share of what enters the food supply without direct review.
Consumers who want to act now have limited but real options: reading ingredient labels, which are required regardless of GRAS status, and filing a comment on the docket during the open period. Anyone concerned about a specific ingredient should raise it with a clinician or registered dietitian rather than making dietary changes based on regulatory news alone.
Manufacturers face a different calculation. Industry groups have argued that mandatory notification could slow ingredient development by adding cost and time.
The next milestone is the close of the comment period. After that, the FDA would review submissions before issuing any final rule, a process that commonly takes a year or more for a proposal of this scope.
Key Questions Answered
What is GRAS? It stands for Generally Recognized as Safe, a category of food substances exempt from premarket approval because qualified experts recognize them as safe for their intended use.
What is changing? The FDA has proposed requiring companies to notify the agency when they conclude a substance is GRAS. Notification is currently voluntary.
Does this mean any ingredient has been found unsafe? No. The proposal is a reporting and transparency requirement. It makes no safety determination about any specific substance.
Will products be removed from shelves? No. Nothing is being recalled or banned under this proposal.
When would it take effect? Comments are due by December 9. If finalized, the rule would take effect 60 days after publication of a final rule, with compliance 18 months later.
Can the public weigh in? Yes. Comments may be submitted through Regulations.gov under docket FDA-2025-N-3262 during the open period.
Could this be challenged in court? Quite possibly. Industry attorneys have raised questions about whether the FDA can require notification under existing law, and the health secretary has said Congress may need to act.
